文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

核医学影像的新靶点

New Targets for Imaging in Nuclear Medicine.
PubMed 文献 · Semin Nucl Med · 2025-05-06

本文为社论,概述核医学新兴分子影像靶点与计算工具。新型PET与SPECT示踪剂靶向前列腺特异性膜抗原(PSMA)、成纤维细胞激活蛋白(FAP)和tau蛋白,人工智能(AI)与机器学习被整合进示踪剂开发与图像分析,并讨论诊疗一体化及监管、生产与临床挑战。

要点

  • 新型PET与SPECT示踪剂靶向PSMA、FAP和tau蛋白,较传统显像剂可更特异显示疾病过程。
  • AI与机器学习被整合进示踪剂开发与图像分析,可加速放射性药物发现并辅助解读复杂影像数据集。
  • 诊疗一体化将诊断与放射性核素治疗配对,社论同时讨论监管、生产与临床挑战。

核心结论

  • 分子靶向与AI创新有望转变核医学实践,在精准医疗时代实现更个性化的诊断与放射性诊疗一体化策略。

研究设计与样本

  • 本文为社论,概述核医学新兴影像靶点与技术,未报告系统检索方法或样本量。

主要发现

  • 新型PET与SPECT示踪剂靶向前列腺癌的PSMA、肿瘤基质的FAP和神经退行性疾病的tau蛋白。
  • 这些示踪剂较传统显像剂可更特异显示疾病过程,契合肿瘤学与神经病学向精准影像的转变。
  • AI与机器学习被整合进示踪剂开发与图像分析,可加速放射性药物发现、优化药代动力学特性并辅助解读复杂影像数据集。
  • 诊疗一体化应用将诊断与放射性核素治疗配对。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文提到监管、生产与临床方面的挑战必须加以应对。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nuclear medicine is rapidly evolving with new molecular imaging targets and advanced computational tools that promise to enhance diagnostic precision and personalized therapy. Recent years have seen a surge in novel PET and SPECT tracers, such as those targeting prostate-specific membrane antigen (PSMA) in prostate cancer, fibroblast activation protein (FAP) in tumor stroma, and tau protein in neurodegenerative disease. These tracers enable more specific visualization of disease processes compared to traditional agents, fitting into a broader shift toward precision imaging in oncology and neurology. In parallel, artificial intelligence (AI) and machine learning techniques are being integrated into tracer development and image analysis. AI-driven methods can accelerate radiopharmaceutical discovery, optimize pharmacokinetic properties, and assist in interpreting complex imaging datasets. This editorial provides an expanded overview of emerging imaging targets and techniques, including theranostic applications that pair diagnosis with radionuclide therapy, and examines how AI is augmenting nuclear medicine. We discuss the implications of these advancements within the field's historical trajectory and address the regulatory, manufacturing, and clinical challenges that must be navigated. Innovations in molecular targeting and AI are poised to transform nuclear medicine practice, enabling more personalized diagnostics and radiotheranostic strategies in the era of precision healthcare.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Brink A, Paez D, Estrada Lobato E, et al. New Targets for Imaging in Nuclear Medicine. Semin Nucl Med. 2025. PMID: 40335357. doi:10.1053/j.semnuclmed.2025.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。